Principles of Injection Technique Table of Contents
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Nerve Block of Lateral Femoral Cutaneous Nerve of the Thigh
18VTLLAA 1 Nerve block of lateral femoral cutaneous nerve of the thigh. Dr. Robert M Raw (MD) . MBChB, MFGP, MPraxMed, DA, FCA. Professor of Anesthesia retired Editor of Regional-Anesthesia.Com INDEX. 1. Introduction 2. Anatomy 3. Choice of local anesthetic 4. General indications 5. Complications and side effects 6. Conclusion ------------------------------------------------------------------------------------ 1. INTRODUCTION The lateral femoral cutaneous nerve of the thigh (LFCN) is the single human nerve most subject to anatomic variations. Figure #1shows the dermatome of LFCN. The nerve is small and mostly invisible under ultrasound scanning. For nerve block success, drug must be injected into four fascial compartments, each of which a variant nerve type may pass through in different individuals. 2. ANATOMY The lateral femoral cutaneous nerve is a sensory nerve supplying the skin on the lateral aspect of the thigh. That sensory area nearly reaches the thigh posterior midline and the thigh anterior midline. Its superior limit passes over the greater trochanter and its inferior limit nearly reaches the height of the patella. The typical LCNT, in 60% of patients, is a branch of the lumbar plexus deriving from the dorsal divisions of nerve roots L2 and L3. The LFCN forms within the psoas muscle, and exits the pelvis medial to the anterior superior iliac spine (ASIS) and under the inguinal ligament. It then passes over the sartorius muscle, under fascia lata, before branching into its final Figure 1. Classic dermatomal distribution of the divisions. In forty percent of patients the LFCN lateral femoral cutaneous nerve (LFCN), derived has completely different anatomy, but from Sobotta. fortunately the nerve always passes in proximity to the proximal sartorius muscle. -
Intravenous Therapy Procedure Manual
INTRAVENOUS THERAPY PROCEDURE MANUAL - 1 - LETTER OF ACCEPTANCE __________________________________________ hereby approves (Facility) the attached Reference Manual as of _____________________. (Date) The Intravenous Therapy Procedure Manual will be reviewed at least annually or more often when deemed appropriate. Revisions will be reviewed as they occur. Current copies of the Intravenous Therapy Procedure Manual shall be maintained at each appropriate nursing station. I have reviewed this manual and agree to its approval. __________________________ (Administrator) __________________________ (Director of Nursing) __________________________ (Medical Director) - 2 - TABLE OF CONTENTS TABLE OF CONTENTS INTRODUCTION A. Purpose 1 B. Local Standard of Practice 1 RESPONSIBILITIES A. Responsibilities: M Chest Pharmacy 1 B. Responsibilities: Administrator 1 C. Responsibilities: Director of Nursing Services (DON/DNS) 1 D. Skills Validation 2 AMENDMENTS GUIDELINES A. Resident Candidacy for IV Therapy 1 B. Excluded IV Medications and Therapies 1 C. Processing the IV Order 1 D. IV Solutions/Medications: Storage 2 E. IV Solutions/Medications: Handling 3 F. IV Solutions and Supplies: Destroying and Returning 4 G. IV Tubing 5 H. Peripheral IV Catheters and Needles 6 I. Central Venous Devices 7 J. Documentation and Monitoring 8 K. IV Medication Administration Times 9 L. Emergency IV Supplies 10 I TABLE OF CONTENTS PROTOCOLS A. IV Antibiotic 1 1. Purpose 2. Guidelines 3. Nursing Responsibilities B. IV Push 2 1. Purpose 2. Guidelines C. Anaphylaxis Allergic Reaction 4 1. Purpose 2. Guidelines 3. Nursing Responsibilities and Interventions 4. Signs and Symptoms of Anaphylaxis 5. Drugs Used to Treat Anaphylaxis 6. Physician Protocol PRACTICE GUIDELINES A. Purpose 1 B. Personnel 1 C. Competencies 1 D. -
Sodium Chloride Injection USP 0.9% Prefilled Syringes, for Intravascular Use Only ------WARNINGS and PRECAUTIONS ------Initial U.S
HIGHLIGHTS OF PRESCRIBING INFORMATION --------------------- DOSAGE FORMS AND STRENGTHS --------------------- These highlights do not include all the information needed to use • Supplied as a clear, colorless, odorless, sterile solution of Sodium Sodium Chloride Injection USP 0.9% safely and effectively. See Chloride 0.9% for intravenous administration (3) full prescribing information for Sodium Chloride Injection USP • Supplied in 50 mL and 125 mL prefilled syringes (3) 0.9%. ------------------------------- CONTRAINDICATIONS ------------------------------- • None (4) Sodium Chloride Injection USP 0.9% Prefilled Syringes, For Intravascular Use Only ----------------------- WARNINGS AND PRECAUTIONS ----------------------- Initial U.S. Approval: 2006 • Remove all air from the syringe and associated tubing prior to injection. (5.1) ----------------------------INDICATIONS AND USAGE ---------------------------- • For use in flushing compatible contrast agents through Liebel- • May cause fluid overload in patients with congestive heart failure, Flarsheim intravenous administration sets into indwelling severe renal insufficiency, and in clinical states with edema, sodium retention, or hypernatremia. (5.3) intravascular access devices (1) • Establish intravascular catheter patency prior to administration. ----------------------- DOSAGE AND ADMINISTRATION ----------------------- (5.4) • For single patient use only. (2) • Determine the volume of flush based on the imaging procedure, ------------------------------ ADVERSE REACTIONS ------------------------------ -
The Example of Closure Systems for Bottled Wine
Sustainability 2012, 4, 2673-2706; doi:10.3390/su4102673 OPEN ACCESS sustainability ISSN 2071-1050 www.mdpi.com/journal/sustainability Article The Importance of Considering Product Loss Rates in Life Cycle Assessment: The Example of Closure Systems for Bottled Wine Anna Kounina 1,2,*, Elisa Tatti 1, Sebastien Humbert 1, Richard Pfister 3, Amanda Pike 4, Jean-François Ménard 5, Yves Loerincik 1 and Olivier Jolliet 1 1 Quantis, Parc Scientifique EPFL, Bâtiment D, 1015 Lausanne, Switzerland; E-Mails: [email protected] (E.T.); [email protected] (S.H.); [email protected] (Y.L.); [email protected] (O.J.) 2 Swiss Federal Institute of Technology Lausanne (EPFL), 1015 Lausanne, Switzerland 3 Praxis Energia, rue Verte, 1261 Le Vaud, Switzerland; E-Mail: [email protected] 4 Quantis, 283 Franklin St. Floor 2, Boston, MA 02110, USA; E-Mail: [email protected] 5 Quantis, 395 rue Laurier Ouest, Montréal, Québec, H2V 2K3, Canada; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +41-21-693-91-95; Fax: +41-21-693-91-96. Received: 23 July 2012; in revised form: 21 September 2012 / Accepted: 2 October 2012 / Published: 18 October 2012 Abstract: Purpose: The objective of this study is to discuss the implications of product loss rates in terms of the environmental performance of bottled wine. Wine loss refers to loss occurring when the consumer does not consume the wine contained in the bottle and disposes of it because of taste alteration, which is caused by inadequate product protection rendering the wine unpalatable to a knowledgeable consumer. -
Injection Technique 1: Administering Drugs Via the Intramuscular Route
Copyright EMAP Publishing 2018 This article is not for distribution except for journal club use Clinical Practice Keywords Intramuscular injection/ Medicine administration/Absorption Practical procedures This article has been Injection technique double-blind peer reviewed Injection technique 1: administering drugs via the intramuscular route rugs administered by the intra- concerns that nurses are still performing Author Eileen Shepherd is clinical editor muscular (IM) route are depos- outdated and ritualistic practice relating to at Nursing Times. ited into vascular muscle site selection, aspirating back on the syringe Dtissue, which allows for rapid (Greenway, 2014) and skin cleansing. Abstract The intramuscular route allows absorption into the circulation (Dough- for rapid absorption of drugs into the erty and Lister, 2015; Ogston-Tuck, 2014). Site selection circulation. Using the correct injection Complications of poorly performed IM Four muscle sites are recommended for IM technique and selecting the correct site injection include: administration: will minimise the risk of complications. l Pain – strategies to reduce this are l Vastus lateris; outlined in Box 1; l Rectus femoris Citation Shepherd E (2018) Injection l Bleeding; l Deltoid; technique 1: administering drugs via l Abscess formation; l Ventrogluteal (Fig 1, Table 1). the intramuscular route. Nursing Times l Cellulitis; Traditionally the dorsogluteal (DG) [online]; 114: 8, 23-25. l Muscle fibrosis; muscle was used for IM injections but this l Injuries to nerves and blood vessels muscle is in close proximity to a major (Small, 2004); blood vessel and nerves, with sciatic nerve l Inadvertent intravenous (IV) access. injury a recognised complication (Small, These complications can be avoided if 2004). -
Glass Container Styles
Glass Container Styles Glass Bottles & Jars Boston Round Bottles Boston Round Bottles are general use bottles that are perfect for liquids, product storage, and field or plant sampling projects. They feature a round body, rounded shoulders and narrow screw neck opening. These environmentally sensitive bottles help eliminate waste and help to ensure product integrity for long term storage. Clear / Flint Boston Round Bottles offers maximum visibility and sample integrity. Amber & Cobalt Blue Boston Round Bottles protect contents from UV rays and are ideal for light sensitive products. Composite Test Jars Clear / Flint Composite Test Jars are clear wide-mouth straight sided jars that are ideal for sampling and provide maximum content visibility. These bottles are designed without shoulders for maximum storage capacity. French Square Bottles Clear / Flint French Square Bottles provide maximum content visibility. The space saving design saves on shelf and storage space. The wide mouth opening is ideal for mixing, storing and sampling. Graduated Medium Round Bottles Bottle Beakers® also known as Graduated Medium Rounds are excellent for use with biological and pathological specimens, but can also be used for storing industrial laboratory chemicals and reagents. These clear / flint bottles are designed with a slight shoulder for easy pouring and handling. Graduated in ml and ounces. Mix, measure, and store in the same container. Media Bottles Media Bottles are manufactured from PYREX® borosilicate glass for chemical and thermal resistance and can be used for storage as well as mixing and sampling. Regular Media Bottles have permanent white enamel graduations and marking spots. PYREXPlus® Media Bottles have a protective PVC coating helps prevent glass from shattering and reduces spills. -
Preparatory: 1 Venous Access and Medication Administration: 4
Preparatory: 1 Venous Access and Medication Administration: 4 W4444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444444 UNIT TERMINAL OBJECTIVE 1-4 At the completion of this unit, the EMT-Critical Care Technician student will be able to safely and precisely access the venous circulation and administer medications. COGNITIVE OBJECTIVES At the completion of this unit, the EMT-Critical Care Technician student will be able to: 1-4.1 Review the specific anatomy and physiology pertinent to medication administration. (C-1) 1-4.2 Review mathematical principles. (C-1) 1-4.3 Review mathematical equivalents. (C-1) 1-4.4 Differentiate temperature readings between the Centigrade and Fahrenheit scales. (C-3) 1-4.5 Discuss formulas as a basis for performing drug calculations. (C-1) 1-4.6 Calculate oral and parenteral drug dosages for all emergency medications administered to adults, infants and children. (C-2) 1-4.7 Calculate intravenous infusion rates for adults, infants, and children. (C-2) 1-4.8 Discuss legal aspects affecting medication administration. (C-1) 1-4.9 Discuss the "six rights" of drug administration and correlate these with the principles of medication administration. (C-1) 1-4.10 Discuss medical asepsis and the differences between clean and sterile techniques. (C-1) 1-4.11 Describe use of antiseptics and disinfectants. (C-1) 1-4.12 Describe the use of universal precautions and body substance isolation (BSI) procedures when administering a medication. (C-1) 1-4.13 Describe the indications, equipment needed, techniques utilized, precautions, and general principles of peripheral venous cannulation (Including saline locks). (C-1) 1-4.14 Describe the indications, equipment needed, techniques utilized, precautions, and general principles of intraosseous needle placement and infusion. -
22428 Moxifloxacin Statisical PREA
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Translational Science Office of Biostatistics S TATISTICAL R EVIEW AND E VALUATION CLINICAL STUDIES NDA/Serial Number: 22,428 Drug Name: Moxifloxacin AF (moxifloxacin hydrochloride ophthalmic solution) 0.5% Indication(s): Treatment of bacterial conjunctivitis Applicant: Alcon Pharmaceuticals, Ltd. Date(s): Letter date:21 May 2010; Filing date: 18 June, 2010; PDUFA goal date: 19 November 2010 Review Priority: Priority Biometrics Division: Anti-infective and Ophthalmology Products Statistical Reviewer: Mark. A. Gamalo, Ph.D. Concurring Reviewers: Yan Wang, Ph.D. Medical Division: Anti-infective and Ophthalmology Products Clinical Reviewer: Lucious Lim, M.D. Project Manager: Lori Gorski Keywords: superiority, Moxifloxacin hydrochloride ophthalmic solution, bacterial conjunctivitis, bulbar conjunctival injection, conjunctival discharge/exudate TABLE OF CONTENTS TABLE OF CONTENTS................................................................................................................ 2 LIST OF TABLES.......................................................................................................................... 3 1. EXECUTIVE SUMMARY ...................................................................................................... 4 1. 1 Conclusions and Recommendations..................................................................................... 4 1. 2 Brief Overview of Clinical Studies ..................................................................................... -
Informed Consent for Medication, Zyprexa
DEPARTMENT OF HEALTH SERVICES STATE OF WISCONSIN Division of Care and Treatment Services 42 CFR483.420(a)(2) F-24277 (09/2016) DHS 134.31(3)(o) DHS 94.03 & 94.09 §§ 51.61(1)(g) & (h) INFORMED CONSENT FOR MEDICATION Dosage and / or Side Effect information last revised on 04/16/2021 Completion of this form is voluntary. If not completed, the medication cannot be administered without a court order unless in an emergency. This consent is maintained in the client’s record and is accessible to authorized users. Name – Patient / Client (Last, First MI) ID Number Living Unit Date of Birth , Name – Individual Preparing This Form Name – Staff Contact Name / Telephone Number – Institution ANTICIPATED RECOMMENDED MEDICATION CATEGORY MEDICATION DOSAGE DAILY TOTAL DOSAGE RANGE RANGE Antipsychotic / Bipolar Agent Zyprexa oral tablet; Oral: 2.5 mg-50 mg with most doses in Zyprexa Zydis oral the 2.5 mg-20 mg range disintegrating tablet; IM: 5 mg-10 mg per dose, up to 3 doses Zyprexa Intramuscular 24 hours Injection; Long Acting Injectable: 150 mg-300 mg Zyprexa Relprevv IM every 2 weeks, Intramuscluar Injection 300 mg-405 mg IM every 4 weeks (olanzapine) The anticipated dosage range is to be individualized, may be above or below the recommended range but no medication will be administered without your informed and written consent. Recommended daily total dosage range of manufacturer, as stated in Physician’s Desk Reference (PDR) or another standard reference. This medication will be administered Orally Injection Other – Specify: 1. Reason for Use of Psychotropic Medication and Benefits Expected (note if this is ‘Off-Label’ Use) Include DSM-5 diagnosis or the diagnostic “working hypothesis.” 2. -
Aerogen Nebulizer)
Page 1 of Date of Original: 11/15/18 Date of Review: Date of Revision: 9/4/19 Respiratory Therapy POLICY & PROCEDURE MANUAL RIBAVIRIN ADMINISTRATION (Aerogen nebulizer) PURPOSE: 1. Standardize the administration and delivery of ribavirin by aerosol 2. To protect the patient and caregivers by standardizing precautions for ribavirin delivery POLICY: The patient room must be set up according to St Jude’s Environmental Health and Safety policy prior to the administration of Ribavirin. Room preparation is to be done by the nursing staff. *See procedure section below https://home.stjude.org/ehs/Pages/ribavirin-precautions.aspx • Negative pressure room is mandatory for Ribavirin administration. • Preparation of the room is the responsibility of the nursing staff. • Ribavirin will be delivered from pharmacy in primed Aerogen syringe set appropriate for use on the MedFusion 3500 syringe pump. • The syringe pumps will be used, maintained, and stored by the respiratory therapy department. • The PPE cart is the shared responsibility of the respiratory therapist who administers the first dose of ribavirin and the nursing coordinator for that area. • Proper sign including contact precautions and STOP will be shared responsibility of the nursing and respiratory care. • All instances of spilled or leaked ribavirin must be documented in the event reporting system. • Ribavirin may be delivered to a patient during mechanical ventilation in a very specific set of circumstances. The final decision on the use of ribavirin is at the discretion of the ICU physician on service. EQUIPMENT: • Negative pressure room • DeMistifier 2000 HEPA filtration system. • DeMistifier negative pressure bed enclosure with canopy. • MedFusion 3500 Syringe pump • Flowmeter • Aerogen vibrating mesh nebulizer • Delivery Supplies (O2 tubing, O2 reducer, large bore tubing, T adaptor, and aerosol face mask) • Prescribed medication • STOP sign for the door during drug administration PPE • N95 or Positive Air Pressure mask required • Chemo resistant Gown • Double Gloves • Shoe covers PROCEDURE: 1. -
Handbook ESRA
TECHNIQUES HEAD & NECK 4 Intracranial surgery p. 3 Eye blocks p. 5 Face anatomy p. 16 Face particularity p. 23 Ophtalmic nerve blocks p. 27 Maxillary nerve blocks p. 33 Mandibular nerve blocks p. 46 THORAX & ABDOMEN 50 Epidural anaesthesia in Cardio-thoracic surgery p. 50 Ilioinguinal-Iliohypogastric block p. 55 Peri-umbilical & Rectus sheath block p. 57 Pudendal block p. 58 UPPER LIMB 61 Choice of a technique p. 61 Brachial plexus anatomy p. 65 Interscalen block p. 68 Supraclavicular blocks p. 73 Infraclavicular blocks p. 80 Axillary block p. 83 LOWER LIMB 90 Lumbar plexus block p. 90 Iliofascial block p. 100 Obturator block p. 102 Sciatic blocks o Sciatic blocks - parasacral nerve approach p. 109 o Sciatic blocks - posterior popliteal approach p. 115 Ankle blocks p. 119 AXIAL BLOCKS 123 Lumbar epidural p. 123 OBSTETRICS AXIAL BLOCKS 126 Epidural p. 126 PERIPHERAL BLOCKS Pudendal block p. 58 2 Aknowledgement The provenience of the materials included in this handbook is from the Learning Zone on the official site of “European Society of Regional Anesthesia and Pain Therapy”. http://www.esra-learning.com/ 2007 3 HEAD & TABLE OF CONTENTS NECK • Intracranial surgery • Eye blocks • Face anatomy • Face particularity • Ophtalmic nerve blocks • Maxillary nerve blocks • Mandibular nerve blocks • Cervical plexus blocks HEAD & INTRACRANIAL SURGERY NECK Paul J. Zetlaoui, M.D. Kremlin-Bicetre - France In intra-cranial neurosurgery, scalp infiltration aims to prevent systematic and cerebral hemodynamic variations, contemporary of skin incision. The potential morbidity of these hypertension-tachycardia episodes, even in patients profoundly anaesthetized, is secondary in the increase of the cerebral blood flow and in its deleterious consequences on intra-cranial pressure in these compromised patients. -
The Development of an Intramuscular Injection Simulation for Nursing Students
Open Access Technical Report DOI: 10.7759/cureus.12366 The Development of an Intramuscular Injection Simulation for Nursing Students Julia Micallef 1 , Artur Arutiunian 1 , Adam Dubrowski 1 1. Health Sciences, Ontario Tech University, Oshawa, CAN Corresponding author: Adam Dubrowski, [email protected] Abstract Intramuscular (IM) injections are preferred over subcutaneous injections for administering medicine such as epinephrine and vaccines as the muscle tissue contains an increased vascular supply that provides ideal absorption of the drug being administered. However, administering an IM injection requires clinical judgment when choosing the injection site, understanding the relevant anatomy and physiology as well as the principles and techniques for administering an IM injection. Therefore, it is essential to learn and perform IM injections using injection simulators to practice the skill before administering to a real patient. Current IM injection simulators either favor realism at the expense of standardization or are expensive but do not provide a realistic experience. Therefore, it is imperative to develop an inexpensive but realistic intramuscular injection simulator that can be used to train nursing students so that they can be prepared for when they enter the clinical setting. This technical report aims to provide an overview of the development of an inexpensive and realistic deltoid simulator geared to teach nursing students the skill of IM injections. After development, the IM simulators were tested and validated by practicing nurses. An 18-item survey was administered to the nurses, and results indicated positive feedback about the realism of the simulator, in comparison to previous models used, such as the Wallcur® PRACTI-Injecta Pads (Wallcur LLC, San Diego, CA).